In a report published Wednesday, Sterne Agee analyst Greg T. Bolan upgraded the rating on Cardinal Health CAH from Neutral to Buy, and raised the price target from $59.00 to $73.00.
In the report, Sterne Agee noted, “After much thought and analysis, we feel it appropriate to raise our estimates and price target for CAH. Based on our new valuation, we believe investors should actively accumulate CAH shares. We believe superior EPS growth to that of S&P 500 operating EPS warrants a superior valuation multiple to the S&P, and as such, believe investors will outperform the broader markets by owning CAH shares.”
Cardinal Health closed on Tuesday at $60.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in